SOURCE: National Venture Capital Association

National Venture Capital Association

April 30, 2009 08:00 ET

Venture Capitalists Honored for Exceptional Service

Lifetime Achievement Awards for Life Sciences Pioneers James Blair, Brook Byers, Jean Deleage, Anthony Evnin, and Grant Heidrich; Warburg Pincus Awarded for Outstanding Service

BOSTON, MA--(Marketwire - April 30, 2009) - The National Venture Capital Association (NVCA) today honored five pioneering life sciences investors with Lifetime Achievement Awards and the venture capital firm Warburg Pincus with its Outstanding Service Award at the NVCA 2009 annual meeting in Boston. The Lifetime Achievement recipients were James Blair, Domain Associates; Brook Byers, Kleiner Perkins Caufield & Byers; Jean Deleage, Alta Partners; Anthony Evnin, Venrock; and Grant Heidrich, Mayfield Fund. Accepting the Outstanding Service Award on behalf of Warburg Pincus was the firm's co-president Joseph Landy.

Lifetime Achievement in Venture Capital Award

The Lifetime Achievement in Venture Capital Award recognizes NVCA members who have dedicated their professional lives to creating and building successful and highly competitive venture firms as well as portfolio companies that have made a significant contribution to economic growth and innovation in the United States. This year the NVCA is pleased to honor five venture capitalists who, through their vision and tenacity, helped to create the life sciences industry. Life sciences companies today represent more than one third of all venture capital investment and have improved and saved the lives of millions of Americans.

James Blair, Domain Associates - James Blair has been a Partner of Domain since its founding in 1985. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, CoDa Therapeutics, Five Prime Therapeutics, GenVault, Helixis, Meritage Pharma, Microchip Biotechnologies, NeuroPace, and Zogenix. Mr. Blair has more than 35 years' experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the Board level of more than 40 life sciences ventures, including Amgen, Amylin Pharmaceuticals, Applied Biosystems, Aurora Biosciences, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, Nuvasive, Pharmion and Volcano.

Dr. Blair currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University, the Department of Biomedical Engineering at the University of Pennsylvania, and the Board of Counsilors of the USC Stevens Institute for Innovation.

Brook Byers, Kleiner Perkins Caufield & Byers - Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than 50 new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients.

Mr. Byers was the founding President, and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 billion. He is currently on the Board of Directors of ten companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford's Bio-X Advisory Council and the Stanford Eye Council.

Jean Deleage, Alta Partners - Jean Deleage began his venture capital career in 1971 in Paris, France with Sofinnova and started its very successful American subsidiary, Sofinnova, Inc. in 1976 in San Francisco. In 1979, he formed Burr, Egan, Deleage & Co., with Craig Burr and William Egan. During the 1980s and 1990s, BEDCO was a prominent, diversified venture firm. He co-founded Alta in 1996.

Dr. Deleage is an industry leader in biotechnology; he had the vision to start the Alta BioPharma family of funds, one of the very first venture capital initiatives to fund later stage life sciences companies. He was an early investor in many of the leading companies in the field today, including Cephalon, Chiron and Genentech. In 1993, he was awarded the Legion of Honor by the French government in recognition of his career accomplishments.

Anthony Evnin, Venrock - Anthony Evnin joined Venrock in 1974 and built the firm's healthcare franchise, helping to shape the modern biotechnology industry. He started his career as a Research Scientist and Group Leader in Organic Chemistry at Union Carbide and as Director of Product Development at Story Chemical. Six of Dr. Evnin portfolio companies have entered the public market in the last three years and over 29 of his investments have been through an IPO during his Venrock tenure.

Dr. Evnin serves as Trustee Emeritus of Princeton University and as a Trustee of The Rockefeller University. He is focused on building valuable companies that address important medical needs of the world, while providing strong returns for investors.

A. Grant Heidrich, Mayfield - Since 1982, Grant Heidrich, III has been a venture capital investor and since 1983 has been a General Partner with Mayfield Fund, the lead and founding investor in Tularik. Mr. Heidrich has served on the Tularik Board of Directors since 1991.

Through his position at Mayfield, Mr. Heidrich has been a founding board member of many biotechnology and information technology companies including Silicon Graphics Inc., Mips Computer Systems, Inc., Cell Genesys, Inc., Millennium Pharmaceuticals, Inc. and Double Twist.com. Mr. Heidrich was a past president of the Western Association of Venture Capital and served as a director of the National Venture Capital Association.

In presenting the awards to his colleagues, incoming NVCA Chairman Terry McGuire of Polaris Venture Partners put the outstanding careers of these five venture capitalists into context:

"Without these venture capitalists, discoveries that have led to treatments for diseases and debilitating conditions such as cancer, diabetes, MS, HIV, rheumatoid arthritis, epilepsy, anemia, and countless others would have never made it out of the laboratories and into the public domain," said McGuire. "It is quite possible that many of us -- and many of our friends and family -- might not be here today if not for the medical breakthroughs brought to market in large part because of these individuals. Each recipient has played a heroic and unparalleled role in the growth and success of the venture capital and life sciences industries. Their legacies are steeped in innovation, patience, and commitment."

Outstanding Service Award - Warburg Pincus

The Outstanding Service Award recognizes an NVCA member or firm that has committed an extraordinary amount of time, resources and dedication to Association efforts that in turn benefit the entire venture industry.

For more than 35 years, Warburg Pincus has provided unfailing support to the NVCA. The firm has been the source of outstanding Board members including two chairmen, a stalwart supporter of NVCA's Venture PAC, and a consistent contributor to major association projects nationally and in New York State.

With a legacy of more than 40 years, Warburg Pincus has invested more than $29 billion in more than 600 companies in 30 countries around the world. Partnering with superior management teams to create sustainable value, Warburg Pincus helps companies to formulate strategy, conceptualize and implement creative financing structures and recruit talented executives, always drawing on best practices from the firm's portfolio companies.

Warburg Pincus traces its roots to E.M. Warburg & Co., an investment banking and private investment counseling firm founded in 1939 by Eric M. Warburg. In 1966, the firm joined with Lionel I. Pincus & Co., a venture capital, investment and financial consulting firm. Having founded Warburg Pincus, Lionel Pincus and John Vogelstein, who joined in January 1967, brought a "professionalized approach" to venture capital and transformed a boutique investment management business into a private equity leader.

"Since the inception of the NVCA, the support of the professionals at Warburg Pincus has set the standard for commitment to forwarding the ideals and tenets of venture capital industry from both a market and a policy perspective," said Mark Heesen, president of the NVCA. "It is a firm upon which the NVCA has consistently relied to demonstrate the valuable contribution of venture capital investment and to achieve our advocacy goals across multiple legislative and regulatory fronts. It gives the NVCA great pleasure to honor Warburg Pincus for their outstanding service this year."

About National Venture Capital Association

The National Venture Capital Association (NVCA) represents approximately 450 venture capital firms in the United States. NVCA's mission is to foster greater understanding of the importance of venture capital to the U.S. economy and support entrepreneurial activity and innovation. According to a 2009 Global Insight study, venture-backed companies accounted for 12.1 million jobs and $2.9 trillion in revenue in the United States in 2008. The NVCA represents the public policy interests of the venture capital community, strives to maintain high professional standards, provides reliable industry data, sponsors professional development, and facilitates interaction among its members. For more information about the NVCA, please visit www.nvca.org.

Contact Information